Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALC-2218
- Development stage
- Preclinical
- Lead developer
- Korea Arlico Pharm
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ALC-2218 is a generic drug candidate being developed by Korea Arlico Pharm for the treatment of cardiovascular diseases. As a generic formulation, it is intended to be bioequivalent to an existing reference listed drug within the cardiovascular therapeutic area. The specific active pharmaceutical ingredient (API) and the reference drug have not been publicly disclosed in the company's high-level pipeline summaries. The project is part of Korea Arlico Pharm's portfolio expansion in the cardiovascular market, which typically includes treatments for chronic conditions such as hypertension, dyslipidemia, and heart failure.
Beyond the preview
Go deeper on ALC-2218.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALC-2218.